扶正化瘀胶囊联合异甘草酸镁治疗失代偿期肝硬化患者的临床效果

Abstract
Figure/Table
References (22)
Related Citation (12)

Download: PDF (413 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Fuzheng Huayu Capsules combined with Magnesium Isoglycerate on liver function and hepatic fibrosis in patients with decompensated cirrhosis. Methods A total of 120 cases with decompensated cirrhosis hospitalized in Tangshan City Hospital for Infectious Diseases and Affiliated Hospital of North China University of Technology from January 2015 to June 2017 were selected. According to random number table method, the patients were divided into control group and case group with 60 cases in each group. The control group was given conventional liver protection plus Magnesium Isoglycyrrhizate, and the case group was given conventional liver protection plus Magnesium Isoxalate and Fuzheng Huayu Capsules. Both groups were treated for 2 weeks. Clinical efficacy, liver fibrosis index and liver function of the two groups before and after treatment were observed. Results The effective rate was 95.00% in the case group, which was significantly higher than 81.67% in the control group, the difference was statistically significant (P ＜ 0.05). After treatment, compared with before treatment, The levels of total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), layer adhesion protein (LN), type Ⅳ collagen (CIV), hyaluronic acid (HA), and before collagen Ⅲ type (PCⅢ) were decreased, while the levels of albumin (ALB) and cholinesterase (CHE) were increased the difference was statistically significant (P ＜ 0.05). After treatment, liver function and liver fibrosis index TBIL, ALT, AST, LN, CIV, HA, PCⅢ levels decreased, levels of ALB and CHE increased in the two groups, the differences were statistically significant (P ＜ 0.05). After treatment, compared with the control group, levels of TBIL, ALT, AST, LN, CIV, HA, PCⅢ decreased, while the levels of ALB and CHE increased in the case group, the differences were statistically significant (P ＜ 0.05). Conclusion The effect of Fuzheng Huayu Capsules combined with Magnesium Isoserate in the treatment of chronic liver cirrhosis is significant. It can obviously improve the liver function and the degree of liver fibrosis, and it has a synergistic effect.

Key words： Fuzheng Huayu Magnesium Isoglycyrrhizinate Decompensated cirrhosis Liver function Liver fibrosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xiaoyong1 ZHANG Guoshun2

Cite this article:

LI Xiaoyong1 ZHANG Guoshun2. Clinical effect of Fuzheng Huayu Capsules combined with Magnesium Isoglycerate in the treatment of decompensated cirrhosis[J]. 中国医药导报, 2019, 16(11): 138-141.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I11/138

[1] 刘斌，张国顺，杨美荣，等.肝硬化并发食管胃底静脉曲张破裂出血与门静脉血栓形成的危险因素[J].世界华人消化杂志，2016，24（18）：2892-2897.
[2] 张国顺，刘斌，方正亚，等.HBV感染合并酒精性肝病的失代偿期肝硬化患者的临床特征及预后[J].世界华人消化杂志，2016，24（22）：3422-3427.
[3] 刘桂勤，沈加林.肝硬化影像学诊断新进展[J].中华实用诊断与治疗杂志，2014，28（2）：112-114.
[4] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2015年更新版）[J].临床肝胆病杂志，2015，31（12）：1941-1959.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南（2010年版）[J].中华肝脏病杂志，2010， 18（3）：167-170.
[6] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].中华肝脏病杂志，2015，23（11）：810-820.
[7] 危北海，张万岱，陈治水，等.肝硬化中西医结合诊治方案[J].现代消化及介入诊疗，2005，12（2）：2694-2696.
[8] Holmberg SD，Lu M，Rupp LB，et al. Non-invasive serum fibrosis markers for screening and staging chronic hepatitis C virus（HCV）patients in a large US cohort [J]. Clin Infect Dis，2013，43（2）：240-246.
[9] 黎莉，杨卫文，魏涛，等.乙型肝炎肝硬化并发原发性肝癌的危险因素Logistic分析[J].中国老年学杂志，2016， 36（7）：1653-1654.
[10] 王贺，王千钧，孙风波，等.恩替卡韦联合扶正化瘀胶囊对代偿期慢性乙型肝炎肝硬化患者炎性因子及纤维化指标的影响[J].临床肝胆病杂志，2016，32（9）：1734-1738.
[11] 赵子龙，康海燕，张志，等.阿德福韦酯联合拉米夫定与恩替卡韦单药治疗乙肝肝硬化疗效比较[J].现代中西医结合杂志，2016，25（33）：3716-3718.
[12] 王守兵，刘星，孟召刚.扶正化瘀胶囊联合恩替卡韦分散片治疗乙型肝炎肝硬化32例疗效观察[J].肝脏，2016， 21（1）：77-78.
[13] 李学冬.扶正化瘀胶囊联合恩替卡韦治疗慢性乙型肝炎对患者肝纤维化、T淋巴细胞亚群、肾功能的影响及疗效评价[J].河北医药，2016，38（14）：2158-2160.
[14] 李志强，夏春辉，刘孜卓，等.异甘草酸镁注射液治疗肝硬化患者有效性和安全性的系统评价[J].实用肝脏病杂志，2015，18（4）：383-386.
[15] 张红星，刘旭东，吴辉坤.扶正化瘀胶囊对慢性乙型肝炎肝硬化患者炎性因子的影响[J].中西医结合肝病杂志，2016，26（1）：4-5.
[16] 应茵，吴波明.扶正化瘀胶囊联合恩替卡韦片对改善乙型肝炎肝硬化程度效果观察[J].中华中医药学刊，2016， 34（4）：1012-1014.
[17] 王贺，王千钧，孙风波，等.恩替卡韦联合扶正化瘀胶囊对代偿期慢性乙型肝炎肝硬化患者炎性因子及纤维化指标的影响[J].临床肝胆病杂志，2016，32（9）：1734-1738.
[18] 谢宏晟，蔡丽敏，颜鸣鹤，等.恩替卡韦联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化的效果观察[J].浙江医学，2016，38（8）：555-557.
[19] 陈晗，杨碧伟，袁满，等.扶正化瘀胶囊对肝纤维化大鼠的防治作用及对结缔组织生长因子表达的影响[J].四川大学学报：医学版，2016，47（2）：197-202.
[20] Sun L，Shen J，Pang X，et al. Phase I safety and pharmacokineticstudy of magnesium isoglycyrrhizinate after single and multiple intravenous dosesin Chinese healthy volunteers [J]. J Clin Pharmacol，2007，47（67）：767-773.
[21] 王清兰，陶艳艳，吕靖，等.扶正化瘀方调节差异微小RNAs表达的抗肝纤维化的作用机制[J].临床肝胆病杂志，2016，32（3）：503-508.
[22] 杨妍，锁忠岐.恩替卡韦联合扶正化瘀胶囊对代偿期慢性乙型肝炎肝硬化患者炎性因子及纤维化指标的影响[J].中国生化药物杂志，2017，37（10）：40-41.